1Bone RC,Balk RA,Cerra FB. ACCP/SCCM definitions for sepsis and organ failure guidelines for the use of innovative therapies in sepsis[J]. Chest, 1992,101:1644- 1655.
2Joan M. The role of C reactive protein in the evaluation and management of infants with suspected sepsis[J].Adv Neonatal Care,2003,3(1):3 -13.
3Povoa P, Almeida E, Moreira P,et al. C-reactive protein as an in dicator of sepsis[J]. Intensive Care Med, 2008, 24: 1052-1056.
4Claeys R,Vinken S,Spapen H,etal. Plasma procalcitonin and C- reactive protein in acute septic shock: clinical and biological corerlates[J]. Crit Care Med, 2002,30(4) :757-762.
5Haweky PM. Mechanisms of resistance to antibiotics[J]. In tensiev Caer Med, 2000,26 : 9 -13.
7Wald R, Quinn RR, Luo J, et al. University of Toronto Acute Kidney Injury Research Group. Chronic dialysis and death among survivors of acute kidney injury requiring dialysis [ J ]. JAMA, 2009, 302(11) : 1179 -1185.
8RENAL Study Investigators. Renal replacement therapy for acute kidney injury in Australian and New Zealand intensive care units: a practice survey[J]. Crit Care Resusc, 2008, 10(3): 225 - 230.
9Uchino S, Bellomo R, Morimatsu H, et al. Continuous renal re- placement therapy: A worldwide practice survey. The beginning and ending supportive therapy for the kidney ( B. E. S. T. kidney) investigators[ J]. Intensive Care Med, 2007, 33 (9) : 1563 - 1570.
10Wakino S, Imai E, Yoshioka K, et al. Clinical importance of Stenotrophomonas maltophilia nosocomial pneumonia due to its high mortality in hemodialysis patients[ J]. Ther Apher and Dial, 2009, 13(3): 193-198.
